Citizens Financial Group Inc. RI Cuts Stock Holdings in Pfizer Inc. $PFE

Citizens Financial Group Inc. RI reduced its stake in shares of Pfizer Inc. (NYSE:PFE) by 39.2% during the first quarter, Holdings Channel reports. The institutional investor owned 283,183 shares of the biopharmaceutical company’s stock after selling 182,415 shares during the quarter. Citizens Financial Group Inc. RI’s holdings in Pfizer were worth $7,952,000 at the end of the most recent quarter.

Several other large investors have also recently modified their holdings of the stock. Fifth Third Bancorp grew its position in Pfizer by 75.1% during the 1st quarter. Fifth Third Bancorp now owns 4,536,233 shares of the biopharmaceutical company’s stock worth $127,377,000 after acquiring an additional 1,945,958 shares during the last quarter. Glass Wealth Management Co LLC lifted its position in Pfizer by 3.2% in the first quarter. Glass Wealth Management Co LLC now owns 92,316 shares of the biopharmaceutical company’s stock valued at $2,592,000 after purchasing an additional 2,835 shares during the last quarter. Sovran Advisors LLC boosted its stake in shares of Pfizer by 25.8% during the first quarter. Sovran Advisors LLC now owns 24,346 shares of the biopharmaceutical company’s stock valued at $650,000 after purchasing an additional 4,988 shares during the period. WealthShield Partners LLC boosted its stake in shares of Pfizer by 9.9% during the first quarter. WealthShield Partners LLC now owns 29,174 shares of the biopharmaceutical company’s stock valued at $819,000 after purchasing an additional 2,629 shares during the period. Finally, Simplicity Wealth LLC grew its holdings in shares of Pfizer by 11.5% in the first quarter. Simplicity Wealth LLC now owns 44,680 shares of the biopharmaceutical company’s stock worth $1,255,000 after purchasing an additional 4,601 shares during the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Trading Up 0.2%

NYSE:PFE opened at $24.21 on Monday. Pfizer Inc. has a one year low of $23.11 and a one year high of $28.75. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.25 and a quick ratio of 0.94. The company’s 50-day simple moving average is $25.37 and its 200 day simple moving average is $26.19. The firm has a market capitalization of $138.01 billion, a P/E ratio of 18.48 and a beta of 0.35.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, beating analysts’ consensus estimates of $0.72 by $0.03. Pfizer had a net margin of 11.83% and a return on equity of 19.44%. The business had revenue of $14.45 billion during the quarter, compared to the consensus estimate of $13.84 billion. During the same quarter last year, the firm earned $0.92 earnings per share. The business’s revenue for the quarter was up 5.4% on a year-over-year basis. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, analysts forecast that Pfizer Inc. will post 2.96 EPS for the current fiscal year.

Pfizer Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Friday, July 24th will be given a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 7.1%. The ex-dividend date of this dividend is Friday, July 24th. Pfizer’s dividend payout ratio (DPR) is 131.30%.

Pfizer News Summary

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: The U.S. FDA approved PADCEV plus Keytruda for muscle-invasive bladder cancer, expanding the label for a key Pfizer/Astellas regimen and potentially opening the door to more sales in oncology. Article: U.S. FDA Approves PADCEV® plus Keytruda® as Neoadjuvant and Adjuvant Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility
• Positive Sentiment: Pfizer’s oncology story also got incremental attention from a completed lorlatinib lung cancer study and other clinical updates, which keep investors focused on the company’s pipeline rather than only its mature products. Article: Pfizer’s Lorlatinib Lung Cancer Study Wraps Up, Offering Fresh Signals for PFE Investors
• Neutral Sentiment: Bank of America lowered its price target on Pfizer to $26 from $27 while keeping a neutral rating, signaling limited upside but no major change in its overall stance. Article: Pfizer had its price target lowered by Bank of America Corporation from $27.00 to $26.00.
• Negative Sentiment: Several market commentary pieces highlighted concerns about Pfizer’s growth outlook and mixed second-quarter expectations, including skepticism about how quickly Seagen-related benefits will show up in results. Article: Pfizer Poised for Mixed Second Quarter, RBC Says

Wall Street Analysts Forecast Growth

Several research analysts recently commented on PFE shares. Wall Street Zen downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Saturday, July 4th. JPMorgan Chase & Co. cut their price target on shares of Pfizer from $30.00 to $28.00 and set a “neutral” rating on the stock in a report on Wednesday, July 8th. CICC Research started coverage on shares of Pfizer in a research report on Thursday, April 16th. They issued an “outperform” rating and a $33.00 price objective on the stock. Guggenheim upped their price objective on shares of Pfizer from $35.00 to $36.00 and gave the company a “buy” rating in a research note on Tuesday, March 24th. Finally, Wolfe Research reiterated an “underperform” rating and set a $26.00 target price on shares of Pfizer in a report on Thursday, May 14th. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, fourteen have given a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $28.56.

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.